eFFECTOR Therapeutics

eFFECTOR Therapeutics Equity

The The Equity of eFFECTOR Therapeutics (EFTR) as of Oct 20, 2026 is -5.80 M USD. In the previous year, The Equity was 3.90 M USD — a change of -248.74% (lower).

Equity

-5.80 MUSD

YoY

-248.74%

Last updated:

In 2023, eFFECTOR Therapeutics's equity was -5.80 M USD, a -248.74% increase from the 3.90 M USD equity in the previous year.

The eFFECTOR Therapeutics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-13.84 M USD
Jan 1, 2020
979,000.00 USD
Jan 1, 2021
17.28 M USD
Jan 1, 2022
3.90 M USD
Jan 1, 2023
-5.80 M USD
The eFFECTOR Therapeutics Equity history
YEAREquityYoY
-5.80 MUSD-248.74%
3.90 MUSD-77.46%
17.28 MUSD+1,665.47%
979,000.00USD-107.07%
-13.84 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

eFFECTOR Therapeutics Stock analysis

What does eFFECTOR Therapeutics do? eFFECTOR Therapeutics Inc, based in Solana Beach, US, is a clinical-stage biopharmaceutical company specializing in oncology drug development. The company focuses on selective translation regulator inhibitors (STRIs), targeting the eIF4F complex and MNK kinase. Its lead candidate tomivosertib, in a Phase 2b trial with KEYTRUDA for metastatic NSCLC, and second candidate zotatifin, in Phase 1/2 trials for solid tumors, are part of its pipeline. The company, listed on January 8, 2021, employs 15 people. eFFECTOR Therapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing eFFECTOR Therapeutics's Equity

eFFECTOR Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding eFFECTOR Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating eFFECTOR Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

eFFECTOR Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in eFFECTOR Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about eFFECTOR Therapeutics stock

The Equity of eFFECTOR Therapeutics is -5.80 M USD in 2023.

The Equity of eFFECTOR Therapeutics changed from 3.90 M USD to -5.80 M USD, representing a -248.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity eFFECTOR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's eFFECTOR Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — eFFECTOR Therapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — eFFECTOR Therapeutics